Introduction
Untoward platelet activation has been identified as an important pathophysiological component of coronary artery disease (CAD) and has led to the development of effective antiplatelet agents that are now considered mainstay therapy for the prevention of acute ischaemic events. 1 Adding clopidogrel to daily aspirin treatment is the basis of antiplatelet therapy in the context of percutaneous coronary interventions (PCIs), as it reduces the risk of stent thrombosis to 1%. 1 -3 However, important interindividual variability in platelet response to clopidogrel has been reported, resulting in a significant proportion of patients displaying suboptimal inhibition of platelet aggregation and an increased risk of thrombotic complications. 4 There is disagreement in the recommendations issued by European and American experts on the conduct to adopt in patients requiring antiplatelet therapy. While the European Society of Cardiology states that routine assessment of platelet aggregation inhibition in patients submitted to either aspirin or clopidogrel therapy, or both, is not recommended, the American College of Cardiology (ACC), the American Heart Association (AHA), and the Society for Cardiovascular Angiography and Interventions (SCAI) recommend that, in patients in whom stent thrombosis may be catastrophic or lethal (unprotected left main, bifurcating left main, or last patent coronary vessel), platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if ,50% inhibition of platelet aggregation is demonstrated. 3, 5 However, no method of quantification of platelet function inhibition by clopidogrel has consensually been recommended. Although light transmission aggregometry (LTA), which measures luminosity as aggregation occurs in adenosine diphosphate (ADP)-stimulated platelet-rich plasma (PRP), is considered by many as the current gold standard in platelet function testing, the technique demands specific knowledge and skills, requires specialized equipments, and is labour-intensive. 6 Fast and easyto-use point-of-care methodologies are now widely available and often employed to assess platelet response to clopidogrel. However, little is known about the comparability or interchangeability of these tests. Hence, we performed this study to evaluate the comparability of four major platelet function assays in assessing platelet inhibition provided by clopidogrel in patients with stable CAD requiring elective angiography.
Methods Patients
Patients were recruited from the pre-angiography outpatient clinic of the Hô pital du Sacré-Coeur de Montréal in Canada and were included if they presented suspected CAD requiring an elective diagnostic coronary angiography. Exclusion criteria were major bleeding disorders or active bleeding; acute myocardial infarction, or unstable angina, with ST-segment changes !1 mm in at least two contiguous electrocardiographic leads at rest or a troponin level .0.06 mg/L, within 14 days of recruitment; stroke within the last 3 months; platelet count ,150 Â 10 9 /L, prothrombin time .1.5 times control, haematocrit ,35%, or haemoglobin level ,100 g/L; alcohol or drug abuse; enrolment in other investigational drug trials within the previous month; the use of thienopyridines, glycoprotein IIb/IIIa inhibitors, warfarin, or acenocoumarol within the prior week; and allergic reaction or any contraindication to clopidogrel or aspirin. This study was approved by the Institutional Scientific and Ethics Review Board, and patients gave written informed consent for participation.
Study protocol and blood sampling
The present study was a planned and pre-specified substudy of a randomized, prospective, double-blind, and placebo-controlled trial evaluating the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective diagnostic coronary angiography with or without PCI. 7 From 20 September 2004 to 18
April 2006, 116 subjects were randomly assigned in a double-blind fashion to one of four groups of clopidogrel dosing regimens 1 week prior to PCI: 300 mg (n ¼ 29) or 600 mg (n ¼ 28) on the day prior to PCI; 300 mg followed by 75 mg daily (n ¼ 31); or 150 mg daily (n ¼ 28) started 1 week before PCI. In addition to the randomized study medication, all patients received 80 mg of enteric-coated aspirin daily for at least 7 days before the procedure and throughout the study period. Four platelet function assays were assessed simultaneously in all patients: LTA and electrical impedance whole-blood aggregometry (WBA) after stimulation with ADP, VerifyNow w P2Y 12 , and Platelet Function Analyzer (PFA-100 w ). Blood was drawn twice, before clopidogrel initiation and just before elective coronary angiography. The first 2 mL of blood, drawn by venipuncture through a 21 gauge needle, was discarded. Then, blood was drawn into evacuated tubes containing 3.2% sodium citrate. All blood samples were processed within 2 h of collection.
Platelet aggregation assessment Light transmission aggregometry
The assessment of platelet function by LTA was considered the gold standard in this study. 6 Platelet aggregation was assessed in PRP at 378C by LTA. PRP was obtained by the centrifugation of citrated whole blood for 10 min at 1000 r. Whole-blood aggregometry 
VerifyNow w P2Y 12
The VerifyNow w P2Y 12 (Accumetrics, San Diego, CA, USA) point-of-care system is based on turbidimetric optical detection of platelet aggregation in whole blood. Blood was drawn into evacuated tubes containing 3.2% sodium citrate provided by the manufacturer. After withdrawal, whole blood was transferred into cartridges containing a combination of 20 mM of ADP and 22 nM of PGE 1 , the latter being added to specifically measure the effect of clopidogrel following P2Y 12 , but not P2Y 1 , ADP receptor activation. As aggregation occurs, the system converts luminosity transmittance results into P2Y 12 reaction units (PRU). Results are reported as either residual platelet aggregation, measured in PRU, or platelet inhibition, defined as the relative change in platelet aggregation from baseline to the time of angiography. Platelet inhibition is calculated as (12residual aggregation/ baseline aggregation) Â 100.
Platelet function analyser (PFA-100) w PFA-100 w (Dade Behring, Deerfield, IL, USA) is a point-of-care assay that assesses platelet aggregation under high shear, mimicking platelet-rich thrombus formation after injury to a small vessel wall under flow conditions. Whole blood was transferred into standard cartridges, and time necessary to occlude a microscopic aperture in a membrane coated with collagen and ADP was measured. The results are reported as closure time (s). As this technology does not measure platelet aggregation directly but rather assesses the time required for clot formation, platelet inhibition cannot be calculated. Thus, the impact of clopidogrel administration is reported as the absolute prolongation of closure time (s) from baseline.
Sample size and statistical analysis
Sample size was not calculated a priori to correlate platelet function results from different assays at the time of diagnostic coronary angiography. Post hoc calculations showed that the study had a power of 80%, with a two-sided a-value of 0.05, to detect a correlation coefficient of at least 0.25 between any of the paired platelet aggregation data sets obtained from the different platelet function assays (PASS 2002, NCSS 2004 statistical software, Kaysville, UT, USA).
Normally distributed continuous variables are presented as mean (standard deviation), non-normally distributed continuous variables as median (inter-quartile range), and categorical variables as frequencies (percentages). Variables were analysed for a normal distribution with the Kolmogorov-Smirnov test. Continuous variables were compared using the paired t-test or the signed-rank test for comparison of paired samples (the Wilcoxon test), and categorical variables were compared using the x 2 or Fisher exact test, when applicable. To account for the randomization group, partial correlations between results obtained with the various assays were calculated. Agreement between assays to evaluate the inhibition of platelet aggregation from baseline (%inhibition) was assessed through the Bland -Altman agreement analysis. This analysis specifically measures bias, which can be defined as a systematic error responsible for either under-or overestimation of a value, and sets limits agreement, similar to confidence intervals, which indicate the range of under-or overestimation of one reading in comparison with the other. 10 Agreement among assays to identify patients with insufficient platelet aggregation, as recommended in current American guidelines, was assessed through the k statistic.
A two-sided P-value of ,0.05 was considered significant. Analyses were performed with SPSS 14.0 for Windows (SPSS Institute, Chicago, IL, USA) and GraphPad Prism 5 for Windows (GraphPad Software Inc., San Diego, CA, USA).
Results

Patients
Of the 116 patients studied, 92 (79.3%) were male. Mean age was 60.2 + 9.0 years (range from 38 to 80 years). Eight (6.9%) were diabetic, 75 (64.7%) had hypertension, 100 (86.2%) suffered from dyslipidaemia, and 28 (24.1%) were active smokers. After diagnostic angiography, PCI was performed in 33 patients (28.4%). The remaining 83 patients were classified as either presenting nonsignificant stenosis (n ¼ 31) or stenoses not requiring or amenable to PCI (n ¼ 52).
Platelet aggregation studies
All patients underwent the analysis of platelet aggregation by LTA, WBA, and PFA-100 w . However, owing to irregularities in cartridge supply, VerifyNow w P2Y 12 assay was performed in only 72 subjects. All platelet function assays were able to discern a statistically significant difference in platelet function following clopidogrel intake, however to varying degrees ( Figure 1) . With most assays, clopidogrel ingestion resulted in a major inhibitory shift in platelet aggregation profiles, although some overlap between baseline and post-clopidogrel values was notable ( Figure 1A -E) . On the other hand, the prolongation of closure time found with PFA-100 w , although statistically significant, was small and resulted in almost superimposable platelet aggregation profiles obtained at baseline and post-clopidogrel administration ( Figure 1F ).
Inter-test correlations
Baseline Before clopidogrel initiation, subjects displayed important variability in platelet function (Figure 1) . Table 1 and Figure 2A show Spearman's coefficients of correlation between the various platelet function assays. When the same assay was employed using different concentrations of the same agonist, correlation between results was strong. However, results obtained with different assays yielded no or low correlation. Thus, results obtained through LTA and WBA were associated poorly among themselves (0.2 , r , 0.4), and point-of-care assays, namely VerifyNow w P2Y 12 and PFA-100 w , lacked correlation with any of the assays studied (r , 0.2).
After clopidogrel administration
Following clopidogrel administration, wider inter-subject variability was present ( Figure 1 ). As at baseline, the use of different concentrations of an agonist with the same assay resulted in highly correlated results ( Table 2 and Figure 2B ). The association between most analysed pairs of assays improved slightly compared with what was observed at baseline, but remained poor.
Agreement among assays in measuring clopidogrel-induced platelet inhibition
The agreement between clopidogrel-induced platelet inhibition results among platelet function assays was studied by the BlandAltman analysis of agreement. As ADP-induced LTA is the generally accepted gold standard in platelet function testing, we first compared platelet inhibition reported by both concentration of ADP with this methodology (Figure 3) . The inhibition of platelet aggregation induced by ADP 5 and 20 mM showed a slight bias of 4.5% [95% confidence interval (95% CI) 1.3-7.7, P ¼ 0.006 by paired t-test], indicating greater inhibition when 5 mM of ADP was used. However, the limits of agreement varied from 229 (95% CI from 234 to 225) to 38% (95% CI 34-42), indicating that the two ADP concentrations may significantly disagree in certain individuals (Figure 3) .
Since the ADP concentration most commonly used in the literature is 20 mM, the extent of platelet inhibition measured by WBA and VerifyNow w P2Y 12 was compared with that obtained with 20 mM ADP-induced LTA. Because the PFA-100
w assay results cannot be converted into %inhibition, the assay has been excluded from agreement analysis.
The inhibition of platelet aggregation was overestimated by 13% [95% CI 2.9 -24.0, P ¼ 0.01, limits of agreement 297 (95% CI 2112 to 282) to 124% (95% CI 109-139)] when 5 mM ADP-induced WBA was used and underestimated by 11% [95% CI 220.7 to 21.8, P ¼ 0.02, limits of agreement 2110 (95% CI 2123 to 297) to 87% (95% CI 74-100)] when 20 mM ADP-induced WBA was used in comparison with 20 mM ADP-induced LTA ( Figure 4A and B) . 
Agreement among assays to identify patients with insufficient platelet inhibition
Current guidelines by ACC/AHA/SCAI without any supporting evidence state that adjusting the clopidogrel dose may be considered if ,50% inhibition of platelet aggregation is detected on clopidogrel therapy. 3 Results were reanalysed seeking to investigate whether clinical conduct in such a context would be influenced by the platelet function-testing methodology chosen. Insufficient platelet inhibition (,50%) was found in 55% of patients by 5 mM ADP-induced LTA, 66% of patients by 20 mM ADP-induced LTA, 71% of patients by 5 mM ADP-induced WBA, 47% of patients by 20 mM ADP-induced WBA, and 61% of patients by VerifyNow w P2Y 12 . Overall, agreement was poor, as assessed by the k statistic and presented in Table 3 . Although WBA failed to select the same patients as candidates for intensified therapy as either LTA or VerifyNow w P2Y 12 , the latter showed fair agreement with LTA, with 20 mM of ADP yielding better results. The only results displaying strong agreement were the different ADP concentrations used in LTA, thus suggesting that ADP concentration plays a minor role in quantifying platelet response to clopidogrel when assessed optically.
Discussion
Ability to identify patients with insufficient platelet inhibition by clopidogrel using different platelet function assays varies greatly according to the platelet function assay used, and correlation between the tests is poor. Although all assays studied were found sensitive to clopidogrel therapy, none could distinguish categorically patients who were treated with clopidogrel from those who were not. Comparability between assays was low, both at baseline and after clopidogrel intake, as demonstrated by poor agreement through the Bland-Altman analysis of clopidogrelinduced platelet inhibition. Recommendation to increase clopidogrel dosing if insufficient platelet inhibition by clopidogrel is demonstrated, as suggested in the current ACC/AHA/SCAI Assessing inhibition of platelet function guidelines, would benefit from a revision to specify platelet function assay selection, as the current available assays are clearly not interchangeable. A number of studies have looked at the correlation between various assays in defining platelet response to clopidogrel. 11 -13 Although the use of correlation to report on the association between two measurements is widespread, it is often inappropriate as it does not imply agreement between methods, nor does it evaluate bias.
14 To weigh one method against another, or to assess how closely two measurements are related, the BlandAltman agreement analysis was used in this study to overcome the shortcomings of correlation. Thus, this study expands on our current understanding of how each assay measures up against the rest. LTA is considered by many as the gold standard in platelet function testing. 6 In addition to having been used extensively in the last 50 years, it remains to this day the most widely used assay in the assessment of platelet response to clopidogrel, and it targets, with the use of ADP as the agonist, the platelet activation pathway inhibited by clopidogrel, namely the purinergic pathway. Even though the assay has become better automated, it remains timeand labour-intensive, requires technical expertise, and thus is restricted to specialized laboratories. Its major drawback however is the lack of standardization, which renders the assay results hard to compare between research teams. 15 As this study is a single-centre study and all analyses were performed by a single highly trained and experienced technician, the latter limitation of LTA could be avoided, thus minimizing the variability of LTA and resulting in more precise measurements. Predisposing conditions that can create disparities in results between laboratories include different blood specimen temperatures, choice of anticoagulant agent, varying delays of testing from blood collection, adjustment of platelet count to a pre-specified level in the PRP specimen, varying ADP concentrations, and quantification of platelet aggregation at maximal levels vs. at the end of the experiment. 15, 16 Although each of these variables affects the outcome of aggregometry measurement and interpretation, LTA remains among the leading platelet function testing tools to evaluate platelet response to clopidogrel. Although WBA is seldom used in the literature to evaluate platelet response to clopidogrel (like LTA, it remains restricted to specialized laboratories), the poor correlation found between WBA and LTA results in the current study is consistent with a recent report, which described a similar correlation (r ¼ 0.257) between 20 mM ADP-induced LTA and WBA in 27 patients scheduled to undergo PCI. 17 Similarly, in 17 healthy volunteers, 20 mM ADP-induced LTA and WBA disagreed significantly in identifying patients with .50% inhibition of platelet aggregation. 18 In comparison with LTA, aggregometry measured in whole blood requires less manipulation of the specimen, thus making the assay less prone to artefactual platelet aggregation during preparatory steps. 19, 20 It also offers the advantage of a more physiologically relevant milieu for platelets, said to be more sensitive to the antiplatelet effect of clopidogrel. 21, 22 However, the presence of other blood constituents alters platelet aggregation profiles and produces less consistent results than those obtained in PRP. 23 Erythrocytes and leukocytes have been shown to actively regulate the availability of ADP in blood, and higher doses of ADP are believed to be necessary to elicit platelet aggregation in whole blood. 21, 24 This particularity may explain the important variability detected in whole blood clopidogrel-induced platelet inhibition in our study and the subsequent lack of agreement with LTA results obtained with the same agonist concentrations.
In an effort to make platelet function testing widely available outside of specialized laboratories, several point-of-care assays have been commercialized. The VerifyNow w P2Y 12 assay was developed and Food and Drug Administration-approved to specifically evaluate the effect of P2Y 12 receptor blockade on platelet aggregation. This technology offered the novelty of isolating the effect of ADP stimulation on the P2Y 12 receptor from that of the P2Y 1 receptor, by incorporating the effects of PGE 1 in addition to ADP. 25 This design aimed at limiting the variability of response to clopidogrel by removing the contribution of the P2Y 1 ADP receptor, which is unaffected by clopidogrel administration. However, our results and others published recently detected significant variability in platelet aggregation measured with this device, with an important overlap between pre-and postclopidogrel values. 26 In comparing these results with those obtained through LTA, we found weak-to-moderate correlation, which contrasts with recent reports describing a much stronger correlation (0.73 , r , 0.86) between these methodologies.
11,12
Moreover, we found that agreement between these methodologies in selecting patients with insufficient platelet inhibition was low, concordant with a recent report on 1267 patients admitted for acute coronary syndrome. 13 We further compared the VerifyNow w P2Y 12 device results with those obtained through WBA, as the VerifyNow w P2Y 12 device also requires a whole-blood specimen. It is worth mentioning that the disadvantages of whole-blood specimens apply to the VerifyNow w P2Y 12 technology as well. The association between the VerifyNow P2Y 12 results and WBA was not improved in comparison with LTA. It also resulted in a complete lack of agreement in selecting patients with insufficient clopidogrel-induced platelet inhibition.
The PFA-100 w is another point-of-care device intended for the detection of platelet dysfunctions. However, our results are in agreement with several reports describing its inability to monitor clopidogrel therapy. 27 -30 As described previously, although a statistical difference could be detected, clopidogrel ingestion did not result in a major inhibitory shift of platelet aggregation. Furthermore, the PFA-100 w results lacked meaningful correlation with all other platelet function assays studied, in accordance with previous studies. 28, 30 As the assay cannot quantify the inhibition of platelet aggregation by clopidogrel from baseline, it fails to highlight patient populations requiring intensified therapy and, as such, is inadequate to evaluate the effect of clopidogrel.
Limitations
As this report is a substudy, some limitations are inherent to the study design. Mainly, the sample size was not determined beforehand, and the analysis was conducted post hoc of the parent randomized, double-blind, placebo-controlled trial. 7 However, power calculations demonstrated sufficient power to detect Assessing inhibition of platelet function clinically meaningful correlations between assay results. Although clopidogrel metabolites were not measured to ensure that patients took clopidogrel, compliance was verified by pill count and personal interview. The cut-off value of 50% to indicate inadequate clopidogrel-induced platelet inhibition is arbitrary, and no strong evidence indicates that this cut-off is a predictor of adverse cardiovascular events. However, this cut-off value is recommended by the current American guidelines as an indicator of insufficient platelet inhibition by clopidogrel and has therefore been selected as most relevant herein. It should be noted that this study was not designed to evaluate the clinical utility of platelet inhibition measurements. The small sample size precludes us from stating that either test is better suited to do so. However, the current study highlights that the available platelet function assays are not interchangeable and thus the recommendation to use available platelet function tests interchangeably to screen non-responders to clopidogrel is premature.
Several other platelet function assays are available to evaluate clopidogrel-induced platelet inhibition. Some examples include the flow cytometric measurement of the vasodilator-stimulated phosphoprotein (VASP) phosphorylation status, the Thromboelastograph w , and Plateletworks w . As these techniques were not evaluated in the current study, their comparability with present platelet function assays cannot be discussed. However, because the VASP index is highly P2Y 12 -specific, it may prove more sensitive to the evaluation of clopidogrel-induced platelet inhibition. 4 
Conclusion
At present, no platelet function assay can be acclaimed as optimal for quantifying the inhibition of platelet aggregation by clopidogrel. Although most studied assays were sensitive to clopidogrelinduced platelet inhibition, the results showed only weak association among platelet function test results, and agreement between tests to select patients requiring intensified clopidogrel therapy was accordingly low. Consequently, before implementing guidelines influencing clinical decision as recommended by recent American guidelines, 3 the assay and cut-off values that should be used to direct medical conduct in terms of clopidogrel therapy need to be specifically evaluated. At the present time, we believe that more work needs to be done to better understand the shortcomings of various platelet function assays. Large prospective clinical trials are necessary to determine the clinical value of platelet function tests, and their use in a clinical setting should therefore be avoided as long as the results of such studies are pending. 
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